#United States #Eurofins Viracor #Lenexa #BKV inSIGHT™ #T-Cell Immunity

Eurofins Viracor Unveils BKV inSIGHT™ T-Cell Immunity Panel

In a significant advance for kidney transplant health management, Eurofins Viracor has announced the launch of the BKV inSIGHT™ T-Cell Immunity Panel (TCIP), designed to facilitate the monitoring of BK virus (BKV)-specific immunity in transplant patients. This novel assay is pivotal for patients experiencing notable BK viremia shortly after a kidney transplant, providing clinicians with essential data to evaluate the patient’s immune response to the virus.

The Challenge of BK Virus in Transplant Patients

BK virus is a formidable concern for individuals who have undergone kidney transplantation due to its potential to cause serious complications. Post-transplant, the standard protocol often entails immunosuppressive therapy to prevent organ rejection, inadvertently increasing the risk of opportunistic infections like BK virus. Monitoring BKV infection levels and the body’s immune response has thus become vital for effective patient management.

The new BKV inSIGHT™ T-Cell Immunity Panel, identified by Test Code 33591, allows for the assessment of T-cell immunity specific to BK virus, aiding in clinical decision-making. The test aims to determine if patients can regain immunological control over their BK virus levels. Crucially, it can identify patients who exhibit adequate immune responses, potentially leading to tailored strategies for managing ongoing immunosuppression.

Key Features of the BKV inSIGHT™ T-Cell Immunity Panel

The BKV inSIGHT T-Cell Immunity Panel offers several groundbreaking features:

• - Targeted Measurement: The test specifically measures the T-cell immune response against BK virus, thus supporting clinicians in determining the most effective immune-modulating strategies.
• - Timely Evaluation: It is intended for patients who exhibit BK viral loads of over 1,000 IU/mL, ideally assessed within 30 days of detection to prompt timely intervention.
• - Predictive Insights: An important finding from recent studies indicates that a detectable level of BKV-specific immunity correlates with a higher chance of achieving a significant reduction in viral load within approximately 30 days following the test.
• - Efficient Testing Protocol: The sample collection is straightforward, utilizing sodium heparin tubes for whole blood. Samples are required to be shipped overnight on the same day as collection to ensure accuracy. The results are processed via flow cytometry with a turnaround time of approximately 3-4 business days.

Implications for Clinical Practice

The introduction of the BKV inSIGHT™ T-Cell Immunity Panel is expected to significantly enhance the management of BK virus infection in kidney transplant recipients. According to Eurofins Viracor, the test is not yet approved by the U.S. Food and Drug Administration, but it represents a critical advancement in monitoring immunological responses in transplant medicine. The firm believes this panel will provide a novel tool for healthcare providers, facilitating a more comprehensive monitoring strategy for patients at risk of BK virus-related complications.

The launch of the BKV inSIGHT™ T-Cell Immunity Panel reflects Eurofins Viracor’s commitment to innovating diagnostic services and enhancing patient outcomes in high-risk populations, including those undergoing organ transplantation.

About Eurofins Viracor

Eurofins Viracor has been a leader in diagnostic testing for over 40 years, specializing in infectious disease, immunology, and allergy tests for patients with compromised immune systems. As part of Eurofins Scientific, a globally recognized bio-analytical testing company, Viracor strives to deliver precise and timely results, maintaining a firm connection between testing and patient care. For more information, visit eurofins.com and eurofins-viracor.com.